A population-based study examined the cancer risk in patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). The study used administrative data from Manitoba's health insurance system to compare cancer incidence rates between IBD patients and a matched non-IBD population. The results showed increased cancer risks for both CD and UC patients compared to the general population. Specifically, CD patients had a higher risk of colon carcinoma (IRR = 2.64) and hepatobiliary carcinoma (IRR = 5.22), while UC patients had a higher risk of colon carcinoma (IRR = 2.75) and rectal carcinoma (IRR = 1.90). CD patients also had a significantly higher risk of small intestine carcinoma (IRR = 17.4) and lymphoma in males (IRR = 3.63). UC patients did not show an increased risk of cancer overall. The study found that the risk of lymphoma in CD patients was not related to immunomodulatory therapy. The study also noted that the risk of colorectal cancer in UC patients increases with disease duration and is associated with primary sclerosing cholangitis. The study concluded that both CD and UC patients have increased cancer risks, with CD patients at higher risk for certain cancers, including lymphoma in males. The study highlights the importance of monitoring cancer risk in IBD patients and underscores the need for further research to understand the underlying mechanisms.A population-based study examined the cancer risk in patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). The study used administrative data from Manitoba's health insurance system to compare cancer incidence rates between IBD patients and a matched non-IBD population. The results showed increased cancer risks for both CD and UC patients compared to the general population. Specifically, CD patients had a higher risk of colon carcinoma (IRR = 2.64) and hepatobiliary carcinoma (IRR = 5.22), while UC patients had a higher risk of colon carcinoma (IRR = 2.75) and rectal carcinoma (IRR = 1.90). CD patients also had a significantly higher risk of small intestine carcinoma (IRR = 17.4) and lymphoma in males (IRR = 3.63). UC patients did not show an increased risk of cancer overall. The study found that the risk of lymphoma in CD patients was not related to immunomodulatory therapy. The study also noted that the risk of colorectal cancer in UC patients increases with disease duration and is associated with primary sclerosing cholangitis. The study concluded that both CD and UC patients have increased cancer risks, with CD patients at higher risk for certain cancers, including lymphoma in males. The study highlights the importance of monitoring cancer risk in IBD patients and underscores the need for further research to understand the underlying mechanisms.